索非布韦治疗慢性丙型肝炎的研究进展

彭焕彦; 杨二娜; 孙殿兴

doi:10.3969/j.issn.1001-5256.2016.04.044

索非布韦治疗慢性丙型肝炎的研究进展

DOI: 10.3969/j.issn.1001-5256.2016.04.044

1. 中国人民解放军白求恩国际和平医院全军肝病中心
2. 河北医科大学研究生院

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2551
- HTML全文浏览量: 31
- PDF下载量: 469
- 被引次数: 0
出版历程
- 出版日期: 2016-04-20

Research advances in sofosbuvir for treatment of chronic hepatitis C

Bethune International Peace Hospital of People′s Liberation Army

摘要

摘要:
近几年慢性丙型肝炎的治疗发生了新的变化,直接抗病毒药物治疗活动性丙型肝炎显示出强大的作用,即使是难治性丙型肝炎也能出现较高的持续病毒学应答。其中索非布韦(SOF)以其抗病毒疗程短,应答率高,甚至对于某些丙型肝炎基因型患者可免干扰素治疗的优势脱颖而出。介绍了SOF的作用机制、临床应用现状以及主要不良反应,指出了其在难治性丙型肝炎患者中的应用前景。
- 肝炎,丙型,慢性 /
- 抗病毒药 /
- 索非布韦 /
- 综述
Abstract:
In recent years,new changes have occurred in the treatment of chronic hepatitis C. Direct- acting antiviral agents have shown powerful efficacy in the treatment of active hepatitis C,and even refractory hepatitis C shows a high continuous virologic response. Among these direct- acting antiviral agents,sofosbuvir( SOF) has the advantages of short course of antiviral treatment and high response rate,and some patients with certain hepatitis C genotypes have no need to receive interferon therapy. This article introduces the mechanism of action,current status of clinical application,and major adverse effects of SOF,and points out its promising future in patients with refractory hepatitis C.
- hepatitis C,chronic /
- antiviral agents /
- sofosbuvir /
- review

HTML全文

参考文献(17)

[1]TE HS,JENSEN DM.Epidemiology of hepatitis B and C viruses:a global overview[J].Clin Liver Dis,2010,14(1):1-21,vii.

[2]NIE AH.Recent advances in HCV NS5B RNA-dependent RNA polymerase inhibitors[J].J Int Pharm Res,2012,39(2):89-103.(in Chinese)聂爱华.丙型肝炎病毒NSSB RNA聚合酶抑制剂研究进展[J].国际药学研究杂志,2012,39(2):89-103.

[3]GANE EJ,STEDMAN CA,HYLAND RH,et al.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C[J].N Engl JMed,2013,368(1):34-44.

[4] LAWITZ E,MANGIA A,WYLES D,et al.Sofosbuvir for previously untreated chronic hepatitis C infection[J].N Engl J Med,2013,368(20):1878-1887.

[5]JACOBSON IM,GORDON SC,KOWDLEY KV,et al.Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options[J].N Engl J Med,2013,368(7):1867-1877.

[6]ZEUZEM S,DUSHEIKO GM,SALUPERE R,et al.Sofosbuvir and ribavirin in HCV genotypes 2 and 3[J].N Engl J Med,2014,370(21):1993-2001.

[7]AFDHAL N,ZEUZEM S,KWO P,et al.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection[J].N Engl J Med,2014,370(20):1889-1898.

[8] AFDHAL N,REDDY KR,NELSON DR,et al.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection[J].N Engl J Med,2014,370(16):1483-1493.

[9]KOWDLEY KV,GORDON SC,REDDY KR,et al.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis[J].N Engl J Med,2014,370(20):1879-1888.

[10]LAWITZ E,SULKOWSKI MS,GHALIB R,et al.Simeprevir plus sofosbuvir,with or without ribavirin,to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOSrandomised study[J].Lancet,2014,384(9956):1756-1765.

[11]KWO P,GITLIN N,NAHASS R,et al.LP14:a phase 3,randomised,open-label study to evaluate the efficacy and safety of 8 and12 weeks of simeprevir(SMV)plus sofosbuvir(SOF)in treatment-nave and-experienced patients with chronic HCV genotype 1infection without cirrhosis:optimist-1[J].J Hepatol,2015,62(2):s270.

[12]FORMAN LM,LEWIS JD,BERLIN JA,et al.The association between hepatitis C infection and survival after orthotopic liver transplantation[J].Gastroenterology,2002,122(4):889-896.

[13]GANE EJ.The natural history of recurrent hepatitis C and what influences this[J].Liver Transpl,2008,14(2):s36-s44.

[14]CURRY MP,FORNS X,CHUNG RT,et al.Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation:an open-label study[J].Gastroenterology,2015,48(1):100-107.

[15]SAMUEL D,CHARLTON M,GANE E,et al.P1232 sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation:results of a prospective,multicenter study[J].J Hepatol,2014,60(1):s499.

[16]FORNS X,PRIETO M,CHARLTON M,et al.O62 sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation[J].J Hepatol,2014,60(1):s26.

[17]SULKOWSKI MS,NAGGIE S,LALEZARI J,et al.Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection[J].JA-MA,2014,312(18):353-361.

施引文献

资源附件(0)

访问统计